Fénébrutinib Versus Placebo ou Adalimumab Dans la Polyarthrite Rhumatoïde : un Essai de Phase II Randomisé, en Double Aveugle (Étude ANDES)
Arthritis Rheumatol. 2020 Sep; 72(9): 1435–1446.In this randomised phase II trial with MTX treatment-refractory RA patients, greater efficacy was observed with fenebrutinib 150 mg once daily or 200 mg twice daily compared to placebo, while response rates were numerically similar to those observed with adalimumab. BTK inhibitors have demonstrated clinical efficacy in B cell malignancies and multiple sclerosis, although there is limited clinical evidence of its efficacy in RA. Fenebrutinib (FEN) an orally active and selective non-covalent inhib...
Upadacitinib en monothérapie chez des patients atteints de polyarthrite rhumatoïde active et recevant une réponse inadéquate au méthotrexate (SELECT-MONOTHÉRAPIE): étude de phase 3 randomisée, contrôlée par placebo et à double insu
Lancet. 2019 Jun 8;393(10188):2303-2311UPA monotherapy showed statistically significant improvements in clinical and functional outcomes versus continuing MTX in MTX inadequate-responder patients with RA. Despite its proven effectiveness and safety, many patients are unable to tolerate MTX due to its side-effects. Therapies that can be used without concomitant MTX therefore, have an important place in RA management. In previous studies, UPA has shown efficacy in combination with stable background csDMARDs in RA patients who are DMARD...
A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
Arthritis Rheumatol. 2015;67(2):334–343.Decernotinib (VX-509; Vertex Pharmaceuticals Incorporated) is a JAK 3 inhibitor currently under investigation for its potential use in the treatment of RA. The potency and selectivity profiles of this oral compound have already been established in previous trials, so this study aimed to establish the efficacy and safety profiles of the drug, in RA patients who have had an inadequate response to at least one DMARD.
Four doses; 25 mg, 50 mg, 100 mg and 150 mg, were evaluated in this placebo...